Innoviva Inc. (INVA) 11.46 $INVA Technical Snapshot on

New Post Public Reply Private Reply Replies (0) Message Board

Jun 20, 2016 at 1:12 PM

Innoviva Inc. (INVA) 11.46 $INVA

Technical Snapshot on Application Software Stocks - Fortinet, Workday, Proofpoint, and Innoviva
PR Newswire - Thu Jun 09, 8:05AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Fortinet Inc. (NASDAQ: FTNT), Workday Inc. (NYSE: WDAY), Proofpoint Inc. (NASDAQ: PFPT), and Innoviva Inc. (NASDAQ: INVA). Learn more about these stocks by accessing their free trade alerts at:
PFPT: 62.57 (+1.39), INVA: 11.46 (+0.44), WDAY: 79.93 (+1.33), FTNT: 33.79 (+0.45)

Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 8:40AM CDT
Glaxo (GSK) and Innoviva (INVA) will file an NDA in the U.S. for the closed triple combination therapy (FF/UMEC/VI) for the treatment of COPD by the end of 2016.
INVA: 11.46 (+0.44), TBPH: 22.95 (+1.13), GSK: 41.69 (+1.36), BMY: 71.35 (+0.68)

Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
PR Newswire - Thu Jun 02, 10:00AM CDT
GlaxoSmithKline plc (LSE: GSK) and Innoviva, Inc. (Nasdaq: INVA) today announced that, following discussions with the US Food and Drug Administration (FDA), GSK has brought forward the plan to file a New Drug Application (NDA) in the US for the once-daily closed triple combination therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; a combination inhaled corticosteroid, longacting muscarinic antagonist, long-acting beta agonist) for patients with chronic obstructive pulmonary disease (COPD). The US regulatory submission is now anticipated by the end of 2016, rather than the first half of 2018, as previously expected.
INVA: 11.46 (+0.44), GSK: 41.69 (+1.36)

Regulatory Update on US Filing Plans for Closed Triple Combination Therapy FF/UMEC/VI in Patients With COPD
Marketwired - Thu Jun 02, 1:00AM CDT
Acceleration of Filing of US New Drug Application Now Expected by End of 2016
INVA: 11.46 (+0.44), GSK: 41.69 (+1.36)

Innoviva to Present at Jefferies 2016 Healthcare Conference on June 10
Marketwired - Wed Jun 01, 3:05PM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 1, 2016) - Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Friday, June 10, at 11:00 a.m. ET at the Grand Hyatt Hotel, New York.
INVA: 11.46 (+0.44)

Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta
Zacks Equity Research - Zacks Investment Research - Wed May 25, 10:21AM CDT
GlaxoSmithKline (GSK) and partner Innoviva reported positive headline data from a phase IIIb chronic obstructive pulmonary disease study on Relvar Ellipta.
INVA: 11.46 (+0.44), ANIP: 53.58 (+0.74), GSK: 41.69 (+1.36), BMY: 71.35 (+0.68)

Salford Lung Study Results Show COPD Patients Treated With Relvar(R) Ellipta(R) Achieve Superior Reduction in Exacerbations Compared to 'Usual Care'
Marketwire Canada - Tue May 24, 5:01AM CDT
Pioneering GSK Study Provides Important New Data on the Effectiveness of Relvar Ellipta (FF/VI) When Used in Everyday Clinical Practice
INVA: 11.46 (+0.44), GSK: 41.69 (+1.36)

Glaxo/Innoviva Unveil SUMMIT Study Data on Breo Ellipta
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:14AM CDT
Glaxo (GSK) and Innoviva (INVA) have announced results of two pre-specified analyses from the SUMMIT study on Breo Ellipta.
INVA: 11.46 (+0.44), ANIP: 53.58 (+0.74), GSK: 41.69 (+1.36), BMY: 71.35 (+0.68)

GSK Presents Efficacy Data for Anoro(R) Ellipta(R) in COPD Patients Who Remained Symptomatic on Tiotropium
Marketwire Canada - Wed May 18, 11:22AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - May 18, 2016) - GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of Anoro® Ellipta® (umeclidinium/vilanterol, 'UMEC/VI'

in patients with moderate chronic obstructive pulmonary disease (COPD) who continued to have symptoms while on tiotropium monotherapy.
INVA: 11.46 (+0.44), GSK: 41.69 (+1.36)

GSK Present New Data From Breo(R) Ellipta(R) SUMMIT Study in Patients With COPD at ATS Conference
Marketwire Canada - Wed May 18, 11:22AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - May 18, 2016) - GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that GlaxoSmithKline plc (GSK) presented new data at the American Thoracic Society (ATS) Conference from two pre-specified analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial. One demonstrated that patients with Chronic Obstructive Pulmonary Disease (COPD) and moderate airflow limitation receiving Breo® Ellipta® (fluticasone furoate/vilanterol or FF/VI 100/25mcg) achieved improvements in exacerbations compared with placebo. The second analysis demonstrated these patients reported similar rates of pneumonia when taking FF/VI 100/25mcg compared with placebo.
INVA: 11.46 (+0.44), GSK: 41.69 (+1.36)

Innoviva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11
Marketwired - Tue May 03, 5:57PM CDT
Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11 at 8:40 a.m. PT, at the Wynn Las Vegas in Las Vegas.
INVA: 11.46 (+0.44)

Innoviva meets 1Q profit forecasts
Automated Insights - Thu Apr 28, 4:25PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Innoviva Inc. (INVA) on Thursday reported first-quarter net income of $4.4 million, after reporting a loss in the same period a year earlier.
INVA: 11.46 (+0.44)

Innoviva Reports First Quarter 2016 Financial Results
Marketwired - Thu Apr 28, 3:05PM CDT
Innoviva, Inc. (NASDAQ: INVA)
INVA: 11.46 (+0.44)

Alexion (ALXN) Q1 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 5:53PM CDT
Alexion (ALXN) will report first-quarter 2016 earnings on Apr 28 before market opens.
BMRN: 84.30 (+0.44), INVA: 11.46 (+0.44), ALXN: 126.44 (+1.24), SNY: 39.30 (+0.94)

What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
Ananya Ghosh - Zacks Investment Research - Tue Apr 26, 3:13PM CDT
ImmunoGen (IMGN) will report third-quarter fiscal 2016 results on Apr 29 before the market opens.
INVA: 11.46 (+0.44), IMGN: 3.40 (+0.08), SNY: 39.30 (+0.94)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rutter Mills Secures $13M in Virginia Injury Cases

The Stakes in Virginia When you drop nine successful injury cases on the scales and they tip over $13 million, that's a story worth dissecting. The two top dogs at Rutter Mills certainly know how to make a splash in the legal puddle, don't they? We're talking about attorneys Adam H. Lotkin and Georgina D. Montgomery here, the legal eagles behind these jaw-dropping...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Protecting Your Family on Halloween: Safety Tips

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Lupin Secures FDA Nod for Key Injectable Drug

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Mexico's Beaches Shine in 2026 Best America Rankings

Mexican Shores Turning Heads in 2026 This isn’t just another wave in tourism news; it’s a tidal shift towards Mexico’s sizzling beaches claiming some prime spots on the global travel stage. If you’ve got an eye for tourism dynamics, listen up because Mexico’s sun-soaked shores just snagged six spots among the top 20 beaches in the Americas, according to the...

Full Sail University Bags Billboard Music School Honor

Full Sail Scores a Billboard Nod — What's the Big Deal? Alright, Full Sail University just snagged a spot on Billboard Magazine's 2026 Top Music Business Schools list. That's no small fry, folks. This Florida institution has been carving out a niche in the music business education scene with a hands-on learning approach that hits the nail right on the head. The Recipe...

Teamsters Secure Landmark Deal for SF Parking Workers

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Aspen Dental Brings Comprehensive Care to Whiteville

Bringing Dentistry Closer to Home Now, Whiteville's dental game just got a power-up, with Aspen Dental setting up shop in town. This isn't just another practice popping up—it's a full-on dental hub offering everything from regular cleanings to emergency tooth fixes. And let’s face it, this area's diverse population needs it. The Man Behind the Chair Guess who’s at...

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

CME Group Unveils First Baseball Futures Market

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...